why choose us

First received: August 18, 2022

Clinical Trial: COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: COVID-19

Study Type: INTERVENTIONAL


Official Title: Safety and Immunogenicity of a Dose of the Sanofi-GSK Monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 Vaccine in Kidney Transplant Recipients With a Persistently Low SARS CoV-2 Antibody Titer (COVID1

Brief Summary: An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay.Up to 80 participants will be enrolled in this study.Eligible participants will receive a dose of the Sanofi-GSK monovalent (B.1.351)CoV2 preS dTM-AS03 COVID-19 vaccine candidate..The primary objective is to determine whether a booster dose of…

Read more